Tasly Pharma’s NR-20201 Receives NMPA Approval for Acute Ischemic Stroke Trial
China-based Tasly Pharma Co., Ltd (SHA: 600535) announced receiving approval from the National Medical Products...
Jiangsu Aidea’s AD108 Receives NMPA Approval for Acute Ischemic Stroke
China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced receiving clinical approval from the National...
Insilico Medicine Closes USD110 Million Series E Round to Advance AI-Driven Drug Pipeline
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced the completion of a USD110 million...
Sanyou Medical Raises RMB214 Million for Stake in SMTP Technology
China-based Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced the completion of a private placement...
Gaush Meditech Receives NMPA Approval for Femtosecond Laser Corneal Refractive Surgery System
Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced receiving market approval from the National Medical Products...
Ipsen Appoints Olivia Brown as Global Head of Neurotoxins, Effective April 1st
France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the appointment of Olivia Brown...
China Medical System’s CMS-D003 Receives NMPA Approval for Clinical Study in oHCM
China Medical System Holdings (CMS; HKG: 0867) announced receiving approval from the National Medical Products...
Zai Lab Submits TIVDAK BLA to China’s NMPA for Cervical Cancer Treatment
Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) announced that a Biological License Application (BLA) for...
Haisco Pharmaceutical’s HSK44459 Receives NMPA Approval for Psoriasis and Atopic Dermatitis Trials
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving approval from the National Medical...
Johnson & Johnson MedTech Gains FDA Clearance for MONARCH QUEST with AI Algorithms
US major Johnson & Johnson MedTech announced receiving U.S. 510(k) regulatory clearance for its MONARCH...
Arvinas and Pfizer Announce Positive Phase III Results for Vepdegestrant in ER+/HER2- Breast Cancer
Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) announced positive topline results from...
Harbour BioMed Launches Élancé Therapeutics to Tackle Obesity Treatment Challenges
China-based Harbour BioMed (HKG: 2142) announced the establishment of Élancé Therapeutics, a new subsidiary focused...
Pierre Fabre Partners with RedRidge Bio on BPA Drug Development for Oncology and Dermatology
France-based Pierre Fabre Laboratories announced an exclusive R&D collaboration and license agreement with Switzerland-headquartered RedRidge...
Visen Pharmaceuticals IPO Launches on Hong Kong Stock Exchange Amid Growth in Endocrine Therapies
China-based Visen Pharmaceuticals, a joint venture between Denmark-headquartered Ascendis Pharma and Vivo Capital, has successfully...
Roche and Zealand Pharma Collaborate to Develop Petrelintide for Weight Management
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced a strategic exclusive collaboration and licensing...
China Issues Guidelines for Informatization of Compact County-level Medical Communities
The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...
CDE Releases 91st Batch of Reference Preparations for Generic Drug Evaluation
China’s Center for Drug Evaluation (CDE) has released the 91st batch of reference preparations for...
China’s NHSA Issues Guidelines for Neurological Medical Services Pricing
China’s National Healthcare Security Administration (NHSA) has released the “Guidelines for the Pricing Project Initiation...
Grand Pharmaceutical Group Reports Strong 2024 Financials with 12.8% Revenue Growth
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) revealed its 2024 financial performance, recording revenues...
Ping An Healthcare Reports 2024 Financial Turnaround with Growth in Healthcare Services
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An...